@article{APS10510,
author = {Hong Yu and Hong-ying Gao and Hua Guo and Gui-zhen Wang and Yi-qing Yang and Qian Hu and Li-jun Liang and Qun Zhao and Da-wei Xie and Yu Rao and Guang-biao Zhou},
title = {Upregulation of wild-type p53 by small molecule-induced elevation of NQO1 in non-small cell lung cancer cells},
journal = {Acta Pharmacologica Sinica},
volume = {43},
number = {3},
year = {2022},
keywords = {},
abstract = {The tumor suppressor p53 is usually inactivated by somatic mutations in malignant neoplasms, and its reactivation represents an attractive therapeutic strategy for cancers. Here, we reported that a new quinolone compound RYL-687 significantly inhibited non- small cell lung cancer (NSCLC) cells which express wild type (wt) p53, in contract to its much weaker cytotoxicity on cells with mutant p53. RYL-687 upregulated p53 in cells with wt but not mutant p53, and ectopic expression of wt p53 significantly enhanced the anti-NSCLC activity of this compound. RYL-687 induced production of reactive oxygen species (ROS) and upregulation of Nrf2, leading to an elevation of the NAD(P)H:quinoneoxidoreductase-1 (NQO1) that can protect p53 by inhibiting its degradation by 20S proteasome. RYL-687 bound NQO1, facilitating the physical interaction between NQO1 and p53. NQO1 was required for RYL-687- induced p53 accumulation, because silencing of NQO1 by specific siRNA or an NQO1 inhibitor uridine, drastically suppressed RYL- 687-induced p53 upregulation. Moreover, a RYL-687-related prodrug significantly inhibited tumor growth in NOD-SCID mice inoculated with NSCLC cells and in a wt p53-NSCLC patient-derived xenograft mouse model. These data indicate that targeting NQO1 is a rational strategy to reactivate p53, and RYL-687 as a p53 stabilizer bears therapeutic potentials in NSCLCs with wt p53.},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/10510}
}